MRI靶向前列腺活检:放射科医生应掌握的知识
经直肠超声引导的系统活检对临床显著前列腺癌的检出敏感度低;多参数MRI的应用使MRI-TRUS融合活检和直接(MRI腔内)引导活检等靶向技术更具价值,这些技术对临床显著前列腺癌的检出率更高。本文以图谱形式阐述这些活检技术的概念,以助安全操作并最大化诊断收益。
要点
- 系统活检对临床显著前列腺癌敏感度低,MRI靶向活检可提高其检出率。
- 靶向活检主要用于系统活检阴性但临床高度怀疑前列腺癌的患者。
- 随着诊断性MRI前移,靶向活检有望替代常规系统活检。
核心结论
- MRI靶向活检技术(MRI-TRUS融合活检和直接MRI引导活检)对临床显著前列腺癌的检出率高于系统活检。
- 这些技术主要用于系统活检阴性但临床高度怀疑前列腺癌的患者,随着诊断性MRI的普及,有望替代常规系统活检。
研究设计与样本
- 图谱式论文,旨在阐述MRI靶向前列腺活检技术的概念,未报告具体研究设计、样本量或参考标准。
临床应用与阅片要点
- 作者旨在通过图谱增强对MRI靶向活检技术概念的理解,以便安全操作并最大化诊断收益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Transrectal ultrasound (TRUS)-guided systematic biopsy, the current gold standard for the detection of prostate cancer, suffers from low sensitivity for clinically significant cancer. The use of diagnostic multiparametric MRI has increased the relevance of targeted biopsy techniques such as MRI-TRUS fusion biopsy and direct (in-bore) MRI-guided biopsy, which have higher detection rate for clinically significant cancer. Although primarily used in patients who remain at high clinical suspicion for prostate cancer despite a negative systematic biopsy, with the increasing use of upfront diagnostic MRI, these biopsies are expected to replace routine systematic biopsies. This pictorial essay aims to enhance our understanding of the concepts of these biopsy techniques so that they can be performed safely and provide maximum diagnostic yield.
引用
- Das CJ, Netaji A, Razik A, et al. MRI-Targeted Prostate Biopsy: What Radiologists Should Know. Korean J Radiol. 2020. PMID: 32691544. doi:10.3348/kjr.2019.0817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。